Verastem announced it received FDA Breakthrough Therapy designation for VS-6766 with defactinib in recurrent low-grade serous ovarian cancer.
If the flag holds, it looks like it could hit around $4.60. Considering adding to my position today. But probably will just hold with what I have.
Looks to me like an ascending triangle breakout. Unfortunately, the volume is fairly week, but we'll see where it takes us.
I plan on taking profits in the yellow area. I might run a trailing stop loss when it enters that area and just let it run.
$vstm
Is VSTM forming a W on a weekly chart?
Decide for yourself.
Resistance @2,7 @4,7 @10,30 and the sky is above 19 $
Good luck and happy trading everyone!
Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the...
Bullish setup formed by 3 red daily candles closing at same price . this pattern can lead to significant price change and RSI signal positively .. bullish long more likely with stoploss at 1.25 (not far away) risk reward (-20% vs +100%). to be watched closely!!
STOCH RSI
- Borderline Overbought
ADX and DI
- DI + indicates uptrend
- ADX starting to get up the mid line may indicate strong uptrend
MACD
- MACD and signal indicator have crossed and is going uptrend
Bollinger bands
- show close tunneling may, may signal uptrend
REMARKS
monitor buy signals + analyse fundamentals
This is my first graph analysis
Chart, Technicals, Cash, Upcoming news....
These guys have a COVID trial that starts June 30th and we have yet to see an 8-k or PR for it.
This is a great time to go long and setup for it....We are looking to finally establish 2.05 support...there are a LOT of shorts to come running home if we do so...
First time we will test with a healthier MACD and CMF on...
VSTM seems to have great potential up to $3 a share, and in the long trend it is below the average range. This past quarter earnings is better than the previous quarter.
The RSI is near the bottom of its range. The MACD, though in a steep decline is showing that the indicators are closing in. With this stock having a history of sharp gains and losses it could be a really nice set up for some very sharp gains. Also note the huge gap down it took April 27 as there could be a nice gap fill.
Note. I am very new so do not make trades...
Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
NASDAQ
